Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-01

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase II trial studies how well a fecal microbiota transplant with or without total gut decontamination works in preventing graft versus host disease in patients exposed to broad-spectrum antibiotics. Fecal microbiota transplantation is the administration by enema of fecal matter (stool) that includes helpful bacteria from a normal, healthy donor. Total gut decontamination uses antibiotics to remove/reduce the amount of bacteria in the digestive system. It is not yet known if a fecal microbiota transplant with or without total gut decontamination works better in preventing graft versus host disease compared to standard immunosuppressive therapies (therapies that lower the normal function of the immune system).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

FMT for MDRO Colonization in Solid Organ Transplant

NCT02816437

Infection Due to Resistant Organism

WITHDRAWN PHASE1

Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease

NCT04280471

Acute Graft Versus Host Disease Gastrointestinal Tract Acute Graft Versus Host Disease Severe Gastrointestinal Tract Acute Graft Versus Host Disease +1 more

WITHDRAWN PHASE1

Autologous Fecal Microbiota Transplantation to Prevent Antibiotic Resistant Bacteria Colonization

NCT03061097

Antibiotic Resistant Strain

COMPLETED PHASE1

Placebo Controlled Study of Fecal Microbiota Transplant (FMT) for a First or Second Episode of C. Difficile Infection in Adults Using a Frozen Encapsulated Inoculum

NCT02343328

Clostridium Difficile

TERMINATED PHASE1

Fecal Transplant for MDR Pathogen Decolonization

NCT02906774

Multi-antibiotic Resistance

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To estimate the proportion of patients who develop acute graft-versus-host disease (GVHD) of the gastrointestinal (GI) tract by day 100 post-transplant for patients randomized to the standard of care, total gut decontamination (TGD) followed by fecal microbiota transplant (fecal microbiota transplantation \[FMT\]) and FMT alone arms.

SECONDARY OBJECTIVES:

I. Overall maximum stage of lower GI tract GVHD by day 100 post-transplant. II. Cumulative incidence of acute GVHD grade II-IV and maximum grade through 6 months.

III. Time to onset of acute GVHD and acute GI GVHD. IV. Incidence of adverse events and serious adverse events. V. Incidence of bacterial blood stream infections through 6 months. VI. Hematologic recovery (neutrophils and platelets). VII. Characterization of the intestinal microbiota at enrollment, pre-FMT / time of engraftment, 2 month post-FMT/ engraftment, onset of gastrointestinal tract (GIT) GVHD, and at study completion (6 months).

VIII. Relapse-free survival at 6 months post-randomization. IX. Non-relapse mortality at 6 months post-randomization. X. Overall survival (OS) at 6 months post-randomization.

OUTLINE: Patients are randomized to 1 of 3 arms.

ARM A (TGD + FMT): Patients receive piperacillin-tazobactam orally (PO) three times daily (TID) and nystatin PO four times daily (QID) until FMT. Patients undergo stem cell transplantation on day 0, then undergo FMT via enema over 5-10 minutes within 3 weeks after transplantation.

ARM B (FMT): Patients undergo stem cell transplantation on day 0, then undergo FMT via enema over 5-10 minutes within 3 weeks after transplantation.

ARM C (STANDARD THERAPY): Patients receive standard of care.

After completion of study treatment, patients are followed up at 100 days and 6 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Graft-versus-host Disease Prevention

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I (TGD + FMT)

Patients receive piperacillin-tazobactam PO TID and nystatin QID. Patients undergo stem cell transplantation on day 0, then undergo FMT via enema over 5-10 minutes within 3 weeks after transplantation.

Group Type EXPERIMENTAL

Fecal Microbiota Transplantation

Intervention Type PROCEDURE

Undergo FMT

Nystatin

Intervention Type DRUG

Given PO

Piperacillin-Tazobactam

Intervention Type DRUG

Given PO

Arm II (FMT)

Patients undergo stem cell transplantation on day 0, then undergo FMT via enema over 5-10 minutes within 3 weeks after transplantation.

Group Type EXPERIMENTAL

Fecal Microbiota Transplantation

Intervention Type PROCEDURE

Undergo FMT

Arm III (standard therapy)

Patients receive standard of care.

Group Type ACTIVE_COMPARATOR

Best Practice

Intervention Type OTHER

Given standard of care

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Best Practice

Given standard of care

Intervention Type OTHER

Fecal Microbiota Transplantation

Undergo FMT

Intervention Type PROCEDURE

Nystatin

Given PO

Intervention Type DRUG

Piperacillin-Tazobactam

Given PO

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

standard of care standard therapy Fecal Material Transplantation Fecal Transplantation FMT Poo Transplant Poop Transplant Stool Transplant Mycostatin Nystex PIPER/TAZO Piperacillin/Tazobactam Zosyn

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who are day -10 pre- to day +30 post-allogeneic hematopoietic cell transplant (AHCT) from any donor or graft source and for any conditioning regimen
* Patients who have received treatment with meropenem or piperacillin-tazobactam (pip-tazo) intravenously (IV) (of at least 24 hours duration) in past 7 days
* Controlled infection defined as hemodynamically stable and not requiring supplemental oxygen of more than 2 liters via nasal cannula
* Patients who are able to take oral medications in suspension form
* Patients who are able to provide informed consent (IC) and comply with all study visits and procedures

Exclusion Criteria

* Patients who are anticipated to require continued broad spectrum antibiotics with meropenem or pip-tazo IV for \> 96 hours post-engraftment such as for known, documented infections necessitating prolonged treatment
* Patients with a prior documented infection with mycormycetes
* Patients who are greater than 2 days from time of neutrophil engraftment post AHCT
* Patients with active enteric infections
* Patients with acute GVHD \>= grade II
* Patients unwilling or unable to undergo the FMT via retention enema procedure
* Patients who have received treatment with an investigational agent within 2 weeks of enrollment
* Patients unable to tolerate oral decontamination regimen of pip-tazo and nystatin due to prior allergy or intolerance of these medications
* Patients with any medical or psychological condition that, in the opinion of the investigator, might interfere with the subject's participation in the trial, pose any additional risk for the subject, or confound the assessments of the subject

Minimum Eligible Age

16 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No